Skip to content

Study · In vitro (cells) · mouse · 2003

8 results

Interaction between the Alzheimer's survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis.

Ikonen M, Liu B, Hashimoto Y, Ma L, Lee KW, Niikura T, Nishimoto I, Cohen P

Proceedings of the National Academy of Sciences of the United States of America15 Oct 2003Cited by 225 (Europe PMC)

PMID14561895 (opens in a new tab)PMCIDPMC240741 (opens in a new tab)DOI10.1073/pnas.2135111100 (opens in a new tab)PepBankPUB-14561895
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In human A172 glioblastoma cells, Humanin but not the F6A-HN mutant inhibited apoptosis induced by IGFBP-3.

    In plain wordsIn cells, humanin reduced IGFBP-3-induced cell death in a human glioblastoma cell line, but a mutant humanin did not.

    Peptide
    Humanin
    Outcome
    DecreaseIGFBP-3-induced apoptosis in glioblastoma cells
    Study

    humann: not reported in source

    A172 glioblastoma cells
    Comparator
    F6A-HN
    Outcome group
    Neuroprotection · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    HN but not F6A-HN inhibited IGFBP-3-induced apoptosis in human glioblastoma-A172.
  2. 02LabIn vitro (cells)Activity measurement

    Humanin did not suppress the IGFBP-3 response in SH-SY5Y neuroblastoma cells or in mouse cortical primary neurons.

    In plain wordsIn cells, humanin did not reduce the IGFBP-3 response in a neuroblastoma cell line or in mouse brain neurons.

    Peptide
    Humanin
    Outcome
    No significant changeIGFBP-3 response in neuroblastoma cells and primary neurons
    Study

    human, mousen: not reported in source

    SH-SY5Y neuroblastoma cells and mouse cortical primary neurons
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast, HN did not suppress IGFBP-3 response in SH-SY5Y neuroblastoma and mouse cortical primary neurons.
  3. 03LabIn vitro (cell-free)Mechanism

    Humanin bound IGFBP-3 with high affinity and specificity in yeast mating, pull-down and ligand blot experiments.

    In plain wordsIn lab tests, humanin stuck tightly and specifically to the protein IGFBP-3.

    Peptide
    Humanin
    Outcome
    Not applicableHN binding to IGFBP-3
    Study

    n: not reported in source

    yeast two-hybrid, pull-down and ligand blot assays
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The physical interaction of HN with IGFBP-3 was determined to be of high affinity and specificity and was confirmed by yeast mating, displaceable pull-down experiments with (His)-6-tagged HN, and ligand blot experiments.
  4. 04LabIn vitro (cell-free)Mechanism

    In cross-linking experiments, Humanin bound IGFBP-3 but did not compete with IGF-I binding to IGFBP-3.

    In plain wordsIn lab tests, humanin bound IGFBP-3 without blocking the binding of IGF-I to IGFBP-3.

    Peptide
    Humanin
    Outcome
    No significant changeHN competition with IGF-I-IGFBP-3 binding
    Study

    n: not reported in source

    cross-linking experiments
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In cross-linking experiments, HN bound IGFBP-3 but did not compete with IGF-I-IGFBP-3 binding
  5. 05LabIn vitro (cell-free)Mechanism

    Competitive ligand dot blot experiments showed that the 18-aa heparin-binding domain of IGFBP-3 is the binding site for Humanin.

    In plain wordsIn lab tests, humanin bound to a short heparin-binding region of the protein IGFBP-3.

    Peptide
    Humanin
    Outcome
    Not applicableHN binding site on IGFBP-3
    Study

    n: not reported in source

    competitive ligand dot blot
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    competitive ligand dot blot experiments revealed the 18-aa heparin-binding domain of IGFBP-3 as the binding site for HN

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 06LabEndogenous levelEx vivo tissueMechanism

    Humanin and IGFBP-3 co-immunoprecipitated from mouse testes, which confirmed the interaction in vivo.

    In plain wordsIn mouse testes, the body's own humanin was found bound to IGFBP-3.

    Peptide
    Humanin
    Outcome
    Not applicableHN and IGFBP-3 co-immunoprecipitation from mouse testes
    Study

    mousen: not reported in source

    testis tissue
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Co-immunoprecipitation of IGFBP-3 and HN from mouse testes confirmed the interaction in vivo.

    This result measures the body's own Humanin. Nobody was given the peptide. It is not evidence about taking it.

Studies that did not test the peptide alone2

In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Humanin.

  1. 07LabNot a test of Humanin aloneIn vitro (cells)Activity measurement

    In primary neurons, IGFBP-3 markedly potentiated the ability of Humanin to rescue cells from Abeta1-43 toxicity.

    In plain wordsIn cells, IGFBP-3 strongly increased how well humanin protected neurons from amyloid-beta toxicity.

    Peptide
    Humanin
    Outcome
    IncreaseRescue from Abeta1-43 toxicity with IGFBP-3 and HN
    Study

    n: not reported in source

    primary neurons
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    In primary neurons, IGFBP-3 markedly potentiated HN rescue ability from Abeta1-43 toxicity.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

  2. 08LabNot a test of Humanin aloneIn vitro (cell-free)Mechanism

    The F6A-HN mutant of Humanin did not bind IGFBP-3 in alanine scanning.

    In plain wordsIn lab tests, a humanin mutant with one changed amino acid did not bind IGFBP-3.

    Peptide
    Humanin
    Outcome
    No significant changeF6A-HN mutant binding to IGFBP-3
    Study

    n: not reported in source

    alanine scanning
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Alanine scanning determined that F6A-HN mutant does not bind IGFBP-3.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.